Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Moderna, Inc.

Net Product Sales

Net Product Sales %Chg

Net Product Sales Common Size

Grant Revenue

Grant Revenue %Chg

Grant Revenue Common Size

Collaboration Revenue

Collaboration Revenue %Chg

Collaboration Revenue Common Size

Collaboration Revenue from Related Party

Collaboration Revenue from Related Party %Chg

Collaboration Revenue from Related Party Common Size

Other Revenue

Other Revenue %Chg

Other Revenue Common Size

Total Revenue

Total Revenue %Chg

Total Revenue Common Size

Cost of Sales

Cost of Sales %Chg

Cost of Sales Common Size

Research and Development

Research and Development %Chg

Research and Development Common Size

Selling, General and Administrative

Selling, General and Administrative %Chg

Selling, General and Administrative Common Size

Total Operating Expenses

Total Operating Expenses %Chg

Total Operating Expenses Common Size

Loss from Operations

Loss from Operations %Chg

Loss from Operations Common Size

Interest Income

Interest Income %Chg

Interest Income Common Size

Other Income, Net

Other Income, Net %Chg

Other Income, Net Common Size

Income Before Income Taxes

Income Before Income Taxes %Chg

Income Before Income Taxes Common Size

Provision for Income Taxes

Provision for Income Taxes %Chg

Provision for Income Taxes Common Size

Net Income

Net Income %Chg

Net Income Common Size

Net Loss Attributable to Common Stockholders

Net Loss Attributable to Common Stockholders %Chg

Net Loss Attributable to Common Stockholders Common Size

Basic

Basic %Chg

Basic Common Size

Diluted

Diluted %Chg

Diluted Common Size

Total Revenues

Total Revenues %Chg

Total Revenues Common Size

Gross Profit

Gross Profit %Chg

Gross Profit Common Size

Gross Profit Margin

Gross Profit Margin %Chg

Gross Profit Margin Common Size

Selling, General & Administrative Expenses

Selling, General & Administrative Expenses %Chg

Selling, General & Administrative Expenses Common Size

Research & Development Expenses

Research & Development Expenses %Chg

Research & Development Expenses Common Size

Operating Profit

Operating Profit %Chg

Operating Profit Common Size

Operating Margin

Operating Margin %Chg

Operating Margin Common Size

Interest and Investment Income

Interest and Investment Income %Chg

Interest and Investment Income Common Size

Non-Operating Income

Non-Operating Income %Chg

Non-Operating Income Common Size

Total Non-Operating Income

Total Non-Operating Income %Chg

Total Non-Operating Income Common Size

Income Before Provision for Income Taxes

Income Before Provision for Income Taxes %Chg

Income Before Provision for Income Taxes Common Size

Consolidated Net Income

Consolidated Net Income %Chg

Consolidated Net Income Common Size

Net Income Attributable to Common Shareholders

Net Income Attributable to Common Shareholders %Chg

Net Income Attributable to Common Shareholders Common Size

Basic EPS

Basic EPS %Chg

Basic EPS Common Size

Diluted EPS

Diluted EPS %Chg

Diluted EPS Common Size

Basic Weighted Average Shares Outstanding

Basic Weighted Average Shares Outstanding %Chg

Basic Weighted Average Shares Outstanding Common Size

Total Shares Outstanding

Total Shares Outstanding %Chg

Total Shares Outstanding Common Size

Diluted Weighted Average Shares Outstanding

Diluted Weighted Average Shares Outstanding %Chg

Diluted Weighted Average Shares Outstanding Common Size

EBITDA

EBITDA %Chg

EBITDA Common Size

Effective Tax Rate

Revenue

EBIT

CapEx

Net Interest Income

Assets

Adjusted EBITDA

Adjusted Net Income

Net Revenue

Average Assets

Adjusted EBIT

Adjusted Revenue

Adjusted EBT

Adjusted Funds From Operations

Income Statement	Sep '25	Jun '25	Mar '25	Dec '24	Sep '24	Jun '24
Total Revenues	1,016	142	108	966	1,862	241
Total Revenues %Chg	-45.4%	-41.1%	-35.3%	-65.6%	1.7%	-29.9%
Net Product Sales
Grant Revenue
Collaboration Revenue
Collaboration Revenue from Related Party
Other Revenue
Cost of Sales	207	119	90	739	514	115
Cost of Sales
Gross Profit	809	23	18	227	1,348	126
Gross Profit Margin	79.6%	16.2%	16.7%	23.5%	72.4%	52.3%
Selling, General & Administrative Expenses	268	230	212	351	281	268
Selling, General and Administrative
Research & Development Expenses	801	700	856	1,122	1,137	1,221
Research and Development
Operating Profit	-260	-907	-1,050	-1,246	-70	-1,363
Operating Margin	-25.6%	-638.7%	-972.2%	-129%	-3.8%	-565.6%
Interest and Investment Income	73	81	90	91	103	111
Interest Income
Non-Operating Income	—	-8	4	29	12	27
Other Income, Net
Total Non-Operating Income	73	73	94	120	115	138
Income Before Provision for Income Taxes	-187	-834	-956	-1,126	45	-1,225
Provision for Income Taxes	13	7	7	-64	8	—
Provision for Income Taxes
Consolidated Net Income	-200	-841	-963	-1,062	37	-1,225
Net Income Attributable to Common Shareholders	-200	-841	-963	-1,062	37	-1,225
Net Loss Attributable to Common Stockholders
Basic EPS	-0.5	-2.1	-2.5	-2.9	0	-3.3
Diluted EPS	-0.5	-2.1	-2.5	-2.9	0	-3.3
Basic Weighted Average Shares Outstanding	390	388	386	385	385	384
Total Shares Outstanding	391	389	387	386	385	384
Diluted Weighted Average Shares Outstanding	390	388	386	385	399	384
EBITDA	-208	-850	-1,011	-1,186	-18	-1,322
Effective Tax Rate	-7%	-0.8%	-0.7%	5.7%	17.8%	—